Marilyn N. Bulloch, PharmD, BCPS, FCCM, SPP

Pharmacists improve outcomes by clarifying and delabeling inaccurate antibiotic allergies.

If approved, gepotidacin (GSK) will be a new oral agent added to the treatment paradigm for urinary tract infections (UTIs).

Pharmacists must consider drug Interactions, allergies, and comorbidities when treating patients with urinary tract infections (UTIs).

Data have shown the potential for the therapy to treat several new conditions.

Specific drugs, foods, and supplements can lead to this condition.

Novel drug development has been focused on the augmentation of the T-lymphocyte response.

The role of the pharmacist in sickle cell disease management revolves around appropriate pain management.

The increased negative health outcomes associated with migraines provide an opportunity for pharmacists in both the inpatient and outpatient setting to support patients.

Many of patients with hepatitis that pharmacists encounter have viral hepatitis, which can be easily remembered as the ABCs of hepatitis.

Pharmacists are an important part of the care team for patients with bleeding disorders, providing services such as medication counseling and reconciliation.

It is essential that women are informed of the risks of potentially teratogenic medications because most birth defects are likely to happen early in pregnancy before women become aware they are pregnant.

Pharmacists’ expertise in medication use has expanded their role to a critical member of the multi-disciplinary care team.

Pharmacists hold a vastly underrecognized role within the care team—a role that offers a unique approach toward the therapeutic management of rare diseases.

This Valentine’s Day, pharmacists can remind patients that they may not need to feel guilty when they indulge in a small piece of chocolate.

Although seemingly basic, handwashing can protect from a variety of illnesses and even decrease antibiotic resistance.

The new guidelines recommend dosing vancomycin to achieve an area under the curve to minimum inhibitor concentration (AUC/MIC) ratio of ≥ 400.